OBJECTIVE: The incidence of @entity715 in @entity1 with @entity1252 ( @entity1252 ) is 25 to 50-fold higher than in the general population; we aimed to define the characteristics of @entity49 ( @entity49 ) and @entity715 ( @entity715 ) to identify the @entity1 at highest risk. METHODS: The study included 219 @entity1 with recent-onset @entity1252 . At baseline, standardized medical history and laboratory tests were done. Followup visits occurred quarterly, and information about damage accrual, comorbidities, and cardiovascular risk factors was updated annually. Main outcome was development of TE after @entity1252 diagnosis. RESULTS: Thirty-five @entity1 (16%) developed TE (27 @entity49 , 8 @entity715 ) during 5.21 years of followup; incidence rate 31/1000 @entity1 -years. Most events (57%) developed within the first year of diagnosis, and 69% were not associated with @entity4555 ( @entity4555 ), determined with 1 method. @entity49 developed earlier than @entity715 (2.0 vs 57.5 mos, p = 0.02). In the multivariate analysis, variables preceding @entity49 included @entity1333 , @entity1985 , dose of @entity229 , and @entity4555 in combination with anti-RNP/Sm antibodies (p < 0.03). @entity1 with @entity715 were older (median age 44 vs 29 yrs, p = 0.04), smokers, and had @entity101 , @entity6 , @entity2299 , at least 2 traditional risk factors, @entity1985 , @entity13092 , and a higher cumulative dose of @entity229 (p < 0.05). @entity4555 in combination with anti-RNP/Sm antibodies was associated with @entity49 and improved the accuracy for predicting it. CONCLUSION: Our study suggests that in @entity1252 , @entity49 and @entity715 have different risk factors. Understanding these differences is helpful for identifying @entity1 at highest risk. The use of @entity4555 plus anti-RNP/Sm for predicting @entity49 deserves further study.

Venous and Arterial XXXX Events in @entity1252 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus'] @entity1333 :: ('MESH:D014657', 'Disease') :: ['cutaneous vasculitis'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus'] @entity49 :: ('MESH:D019851', 'Disease') :: ['VTE', 'venous thrombotic events'] @entity13092 :: ('MESH:D001925', 'Disease') :: ['chronic damage'] @entity4555 :: ('MESH:C531622', 'Disease') :: ['lupus anticoagulant', 'LAC'] @entity1985 :: ('MESH:D009404', 'Disease') :: ['nephrotic syndrome'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'ATE', 'arterial thrombotic events']
@entity715 :: (MESH:D013927,Disease) :: ['Thrombotic']
